By Elias Schisgall

Rezolute shares climbed after the pharmaceutical company said data from a Phase 3 trial of ersodetug for congenital hyperinsulinism supported evidence that the drug is active against hypoglycemia, despite failing to meet the trial's primary or key secondary endpoints.

Shares were up 16% to $2.22 late Wednesday morning. The stock is down 56% in the past year.

Shares plummeted last month after Rezolute said ersodetug failed to meet its goals in the sunRIZE trial of reducing and shortening hypoglycemia events. But the company said Wednesday that the drug did demonstrate reductions in the frequency and time of hypoglycemia events, though not to the level of statistical significance.

"While in the early stages of evaluating study data and understanding the results, learnings in the field of glycemic control and initial observations from sunRIZE inform the Company's belief that the pharmacologic response can translate to clinical efficacy," Rezolute said Wednesday.

Rezolute said it looks forward to engaging with the Food and Drug Administration in the first quarter to discuss the results.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 07, 2026 11:30 ET (16:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.